scholarly journals A Comparative Study: Is Misoprostol as Effective as Oxytocin in Active Management of Third Stage of Labor?

2020 ◽  
Vol 3 (2) ◽  
pp. 272-276
Author(s):  
Prem Raj Pangeni ◽  
Padma Raj Dhungana ◽  
Rajesh Adhikari
Keyword(s):  
Active Management ◽  
P Value ◽  
The Third ◽  
Third Stage Of Labor ◽  
Oral Misoprostol ◽  
Third Stage ◽  
Maternal Morbidity And Mortality ◽  
Misoprostol Group ◽  
Orally Active ◽  
To Receive

Background: The third stage of labor is that period from birth of the infant until the delivery of the placenta. Active management of the third stage of labor plays an important role in reducing maternal morbidity and mortality. Oxytocin is an effective drug in preventing postpartum hemorrhage (PPH) however; it requires a controlled environment and intramuscular administration. Misoprostol is an orally active uterotonic agent,stable at room temperature.The purpose of this study was to compare the efficacy of misoprostol with oxytocin in active management of third stage of labor. Materials and Methods: This was a hospital based study carried out in Paropakar Maternity and Women Hospital, Kathmandu, Nepal during six months period from February 2012 to July 2012. One hundred patients fulfilling inclusion criteria were recruited to receive either 10 unit of IM oxytocin or 600 mcg of oral misoprostol for the management of the third stage of labor. Results: The mean blood loss in misoprostol and oxytocin group was 209±76.7ml and 197±68.8 ml respectively with p value-0.41 which was insignificant. Similarly mean hemoglobin change was also not significant. The additional uterotonics needed in misoprostol was higher (9 cases) than that in oxytocin (5 cases) but it was also not significant. Shivering and fever were significantly high among misoprostol group than in oxytocin group. Conclusion: Efficacy of oxytocin and misoprostol is equal in active management of third stage of labor.

Oral Misoprostol: A Safe and Effective Alternative in Comparison to Conventional Uterotonic Agents in the Active Management of Third Stage of Labor

2009 ◽  
Vol 1 (3) ◽  
pp. 19-23
Author(s):  
Mahmud Ghazala ◽  
Tasnim Nasira ◽  
Fatima Saba
Keyword(s):  
Blood Loss ◽  
Active Management ◽  
Efficacy And Safety ◽  
Safe Alternative ◽  
Third Stage Of Labor ◽  
Oral Misoprostol ◽  
Estimated Blood Loss ◽  
Third Stage ◽  
Misoprostol Group ◽  
To Receive

ABSTRACT Objective To determine the efficacy and safety of oral misoprostol with intravenous oxytocin and syntometrine in the active management of third stage of labor. Methodology 325 women were randomly allocated by convenient sampling to receive either 10 IU of intravenous oxytocin or 10 IU of oxytocin with 0.2 mg of Methergine (syntometrine) or 400 mcg of oral misoprostol at the delivery of anterior shoulder. Main outcome measures were estimation of blood loss > 500 ml, drop in hemoglobin/hematocrit levels and adverse effects of drugs. Results Estimated blood loss was significantly higher in group misoprostol group (p = 0.016) but comparable to oxytocin group (p = 0.40). Drop in hemoglobin level was comparable in all the three groups (p = 0.106). Drop in hematocrit value was significant for misoprostol and syntometrine (p = 0.022) but comparable to oxytocin. Nausea and vomiting was common in oxytocin and syntometrine group whereas fever and shivering was the leading adverse effect in misoprostol group. Conclusion Misoprostol is an effective and safe alternative to intravenous uterotonic agents in the active management of third stage of labor both at tertiary and community level.

A multicentre randomized controlled trial of oral misoprostol and i.m. syntometrine in the management of the third stage of labour

2001 ◽  
Vol 16 (1) ◽  
pp. 31-35 ◽  
Author(s):  
P.S. Ng ◽  
A.S.M. Chan ◽  
W.K. Sin ◽  
L.C.H. Tang ◽  
K.B. Cheung ◽  
...  
Keyword(s):  
Postpartum Haemorrhage ◽  
Controlled Trial ◽  
Haemoglobin Concentration ◽  
Singleton Pregnancy ◽  
The Third ◽  
Oral Misoprostol ◽  
Third Stage ◽  
Misoprostol Group ◽  
Orally Active ◽  
To Receive

Abstract Postpartum haemorrhage accounts for nearly 28% of maternal mortality in developing countries. Syntometrine is an effective and commonly used oxytocic in preventing postpartum haemorrhage, but it requires a controlled storage environment and i.m. administration. Misoprostol is an orally active uterotonic agent. A total of 2058 patients having a singleton pregnancy, low risk for postpartum haemorrhage and vaginal delivery were randomized to receive either 1 ml syntometrine or 600 μg misoprostol for the management of the third stage of labour. There were no significant differences between the two groups in the mean blood loss, the incidence of postpartum haemorrhage and the fall in haemoglobin concentration. The need for additional oxytocic injection was significantly higher in the misoprostol group [relative risk (RR) 1.62, 95% confidence interval (CI) 1.34–1.96], but that of manual removal of placenta was reduced (RR 0.29, 95% CI 0.09–0.87). Shivering and transient pyrexia were more common in the misoprostol group. Oral misoprostol might be used in the management of the third stage, especially in situations where the use of syntometrine is contraindicated and facilities for storage and parenteral administration of oxytocics are limited.

scholarly journals A Comparative Study of Active Management of the Third Stage of Labor IV Methergine and IM Oxytocin

2021 ◽  
pp. 267-272
Author(s):  
K. Sharmila
Keyword(s):  
Blood Loss ◽  
The United States ◽  
Active Management ◽  
P Value ◽  
Negative Effects ◽  
The Third ◽  
Third Stage Of Labor ◽  
Group I ◽  
Third Stage ◽  
The Mean

Postpartum haemorrhage (PPH) has been more common over the last three decades, accounting for 11% of all pregnancy-related deaths in the United States. In the third stage of labour, risk classification and active management are crucial preventative techniques. To avoid negative effects, a multidisciplinary approach to PPH patient care is required. To treat uterine atony, uterotonic medicines like oxytocin are used in combination with manipulative procedures like uterine massage and balloon tamponade. The amount of blood loss, duration of the third stage, need for MRP, incidence of PPH, need for repeated oxytocics, and its side effects were measured in Group I 100 women who were administered injection oxytocin 10 IU injection methergin 0.2 mg IV within one minute of the baby's delivery. The mean blood loss at vaginal delivery in Group I was 100-150 ml and in group I P value 0.027, which was statistically significant .In  Group II was 160-200 ml with P value 0.036, which was statistically significant. The mean duration of third stag labour in Group 1 was 124.6 min and Group 2 was 144.8 min intravenous methergin is a better uterotonic when compared to intramuscular oxytocin to reduce the amount of blood loss at delivery and prevent complications like atonic PPH.

scholarly journals Active management of third stage of labour with low doses of oral misoprostol and oxytocin on low: risk parturient in a Sub-Saharan hospital, Dakar, Sénégal

2017 ◽  
Vol 6 (2) ◽  
pp. 516 ◽  
Author(s):  
Moussa Diallo ◽  
Toura Sylla ◽  
Abdoul Aziz Diouf ◽  
Phillipe Marc Moreira ◽  
Omar Gassama ◽  
...  
Keyword(s):  
Average Rate ◽  
Post Partum ◽  
Low Risk ◽  
University Hospital ◽  
Active Management ◽  
Controlled Clinical Trial ◽  
The Third ◽  
Oral Misoprostol ◽  
Third Stage ◽  
Misoprostol Group

Background: Assess the effectiveness of oral misoprostol as an alternative to oxytocin in the active management of the third stage of labour in Dakar/Senegal.Methods: Randomized controlled clinical trial conducted in the maternity ward of a university hospital on 304 women who had vaginal delivery. These women were randomly assigned into 2 groups based on active delivery conditions: the first group received an oral administration of misoprostol (400 mcg) and the second group 5 IU oxytocin through intravenous route.Results: The average volume of blood loss was 196.55 ml in the misoprostol group and 208.39 ml in the oxytocin group (p=0.63). The incidence of postpartum haemorrhage (>500 cc) was 6.49% in the misoprostol group and 9.33% in the oxytocin group (p=0.358). The average rate of haemo globin decline was 0.38 g/dl in the misoprostol group and 0.29 g/dl in the oxytocin group (p=0.99). The proportion of hyperthermia, shivering, and nausea in the misoprostol and oxytocin groups were respectively: 2.59% against 0.6% (p=0.123), 7.14% against 2% (p=0.001) and 2.59% against 0.6% (p=0.498).Conclusions: In Senegal, Misoprostol despite its side effects, is an effective alternative to oxytocin in the active management of the third stage of labour for low-risk parturient women to reduce the risk of maternal deaths due to post-partum hemorrhage.

scholarly journals Manual Removal of the Placenta after Vaginal Delivery: An Unsolved Problem in Obstetrics

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Fiona Urner ◽  
Roland Zimmermann ◽  
Alexander Krafft
Keyword(s):  
Maternal Morbidity ◽  
Placenta Previa ◽  
Morbidity And Mortality ◽  
Active Management ◽  
Retained Placenta ◽  
Manual Removal ◽  
The Third ◽  
Third Stage Of Labor ◽  
Third Stage ◽  
Maternal Morbidity And Mortality

The third stage of labor is associated with considerable maternal morbidity and mortality. The major complication is postpartum hemorrhage (PPH), which is the leading cause of maternal morbidity and mortality worldwide. Whereas in the event of PPH due to atony of the uterus there exist numerous treatment guidelines; for the management of retained placenta the general consensus is more difficult to establish. Active management of the third stage of labour is generally accepted as standard of care as already its duration is contributing to the risk of PPH. Despite scant evidence it is commonly advised that if the placenta has not been expelled 30 minutes after delivery, manual removal of the placenta should be carried out under anaesthesia. Pathologic adhesion of the placenta in the low risk situation usually is diagnosed at the time of delivery; therefore a pre- or intrapartum screening opportunity for placenta accreta would be desirable. But diagnosis of abnormalities of placentation other than placenta previa remains a challenge. Nevertheless the use of ultrasound and doppler sonography might be helpful in the third stage of labor. An improvement might be the implementation of standardized operating procedures for retained placenta which could contribute to a reduction of maternal morbidity.

scholarly journals COMPARISON OF MISOPROSTOL WITH OXYTOCIN IN THIRD STAGE OF LABOUR

2018 ◽  
Vol 6 (1) ◽  
pp. 19-21
Author(s):  
Nilam Subedi ◽  
Deepanjali Sharma ◽  
Rubby Das
Keyword(s):  
Blood Loss ◽  
Active Management ◽  
Secondary Outcome ◽  
Secondary Outcome Measure ◽  
Medical Sciences ◽  
Third Stage Of Labor ◽  
Third Stage ◽  
Misoprostol Group ◽  
Group 2 ◽  
To Receive

Introduction: Postpartum Haemorrhage (PPH) is one of the leading causes of maternal mortality worldwide. A simple measure to prevent PPH is active management of third stage of labour (AMTSL). This prospective study was conducted in Universal College of Medical Sciences and Teaching Hospital, Tribhuvan University,  Bhairahawa where misoprostol  600  mcg  orally was compared with the standard  oxytocin regime in active management of third stage of labour.Materials and Methods: A total of 100 women were selected to receive either 600 mcg misoprostol orally or 10 IU oxytocin intramuscularly. The incidences of postpartum hemorrhage and side effects were examined.Results: Both groups were comparable in age, parity, gestational age, pre-delivery hemoglobin, and duration of labor. There was no significant differences between the misoprostol and oxytocin groups in terms of blood loss  96% vs 100% had blood loss of < 500 ml, p=0.475). And incidence of PPH  (4% vs 0%). None of the group had severe PPH i.e. blood loss> 1000 ml. The duration of the third stage of labor, a secondary outcome measure was shorter in the misoprostol group than in the oxytocin group (7.02±2.26 SD vs 8.44±4.08 SD, p=0.034). Two women of oxytocin group received a blood transfusion. The adverse effects of shivering and pyrexia were encountered more frequently in the misoprostol than in the oxytocin group (2% vs 38%, p<0.001, P<0.001; and 2% vs 10%, p=0.207). No major surgical intervention for atonic PPH was needed and no maternal deaths occurred in either group.Conclusion: Misoprostol 600 mcg orally is equally as effective as standard oxytocin regime in AMTSL to prevent PPH and can be safely used in the peripheral institutions or by midwives where there is lack of trained personnel and storage facility.Journal of Universal College of Medical SciencesVol. 6, No. 1, 2018, Page: 19-21

Sign in / Sign up

Export Citation Format

Share Document